Insider Selling: Zymeworks (NASDAQ:ZYME) Insider Sells $1,036,047.87 in Stock

Zymeworks Inc. (NASDAQ:ZYME – Get Free Report) insider Paul Moore sold 39,741 shares of the company’s stock in a transaction that occurred on Friday, November 13th. The stock was sold at an average price of $26.07, for a total value of $1,036,047.87. Following the transaction, the insider owned 33,756 shares of the company’s stock, valued at approximately $880,018.92. This trade represents a 54.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Zymeworks Stock Performance

Shares of NASDAQ ZYME opened at $26.04 on Thursday. The business has a fifty day moving average of $27.20 and a two-hundred day moving average of $25.53. Zymeworks Inc. has a 52-week low of $21.52 and a 52-week high of $31.97. The stock has a market cap of $1.80 billion, a PE ratio of 50.08 and a beta of 1.32.

Zymeworks (NASDAQ:ZYME – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.01. The company had revenue of $512.92 million during the quarter, compared to analysts’ expectations of $227.40 million. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The business’s quarterly revenue was up 828.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.26) earnings per share. Analysts predict that Zymeworks Inc. will post 1.31 earnings per share for the current year.

Zymeworks announced that its Board of Directors has approved a stock buyback plan on Monday, November 16th that authorizes the company to buy back $200 million in shares. This repurchase authorization authorizes the company to repurchase up to 10.9% of its shares through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

ZYME has been the subject of a number of research analyst reports. Jefferies Financial Group restated a “buy” rating and set a $52.00 price objective on shares of Zymeworks in a report on Friday, October 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Zymeworks in a report on Thursday, October 15th. HC Wainwright upped their target price on shares of Zymeworks from $55.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday, November 10th. Truist Financial increased their price target on Zymeworks from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, November 10th. Finally, B. Riley Financial reaffirmed a “buy” rating and set a $44.00 target price (up from $40.00) on shares of Zymeworks in a research report on Monday, August 10th. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Zymeworks currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

Get Our Latest Stock Analysis on ZYME

Institutional Investors Weigh In On Zymeworks

Several large investors have recently modified their holdings of ZYME. Nykredit A S acquired a new position in Zymeworks during the second quarter worth $25,000. Sterling Capital Management LLC increased its holdings in shares of Zymeworks by 813.3% during the third quarter. Sterling Capital Management LLC now owns 1,507 shares of the company’s stock valued at $40,000 after purchasing an additional 1,342 shares during the period. State of Wyoming acquired a new stake in Zymeworks in the 2nd quarter valued at about $73,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Zymeworks in the 3rd quarter valued at approximately $96,000. Finally, State of Alaska Department of Revenue acquired a new stake in shares of Zymeworks during the 3rd quarter valued at about $102,000. 92.89% of the stock is owned by institutional investors and hedge funds.

Zymeworks Company Profile

(Get Free Report)

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

Further Reading

Insider Buying and Selling by Quarter for Zymeworks (NASDAQ:ZYME)

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.